Mr. Dodd came upon a Boots booklet in a hospice for the terminally ill – which he correctly describes as, “a very vulnerable community.” The booklet touted homeopathy, which prompted Mr. Dodd to write an email message to Ms. Sue Williamson, the Boots Customer Care consultant. Following his first email inquiry to her on July 7th, he also had some telephone conversations with her giving details of the data in the publication. His June 7th email to her read:
I have read a Boots publication concerning homeopathic medicine in which it is stated that research has proved their efficacy. Will you please provide details of any research in which their efficacy has been proven?
On August 15th – 39 days after his first inquiry – a reply came from Ms. Williamson:
Subject: Leaflet on homeopathic medicine
Reference number 2750220
Hello Mr Dodd
I'm writing further to our conversation some time ago and may I firstly apologize most sincerely for the delay to this reply.
I'm really sorry that I've been unable to obtain a copy of the leaflet you referred to and I'm therefore having difficulty in pursuing this matter any further.
However, I've spoken at length to our Project Manager who is responsible for our range of homeopathic medicines. He has confirmed that unfortunately due to confidentiality we wouldn't be able to share any information concerning the research quoted in the leaflet.
Randi comments: I’ve long been aware of the strong English tendency toward privacy – they seldom even provide a return address on the outside of their posted mail – but this seems rather more than normal reluctance to provide basic, pertinent, information about a business that would be expected to share such important material with interested customers. What could be the dreaded “confidential” information about their safety/efficacy “research” that they would opt to keep from their clients? And, in passing, I find it strange indeed that an officer of the company was not able to obtain a copy of
their own printed literature!